Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

NCT05812430 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Advanced Biliary Tract Cancer

Interventions

DRUG: anlotinib+TQB2450+nab-paclitaxel+cisplatin

Sponsor

The First Affiliated Hospital of Zhengzhou University